rs375350606
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_017950.4(CCDC40):c.648C>A(p.Asp216Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000342 in 1,461,232 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 17/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Synonymous variant affecting the same amino acid position (i.e. D216D) has been classified as Likely benign.
Frequency
Consequence
NM_017950.4 missense
Scores
Clinical Significance
Conservation
Publications
- primary ciliary dyskinesia 15Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae), PanelApp Australia, Laboratory for Molecular Medicine
- primary ciliary dyskinesiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- autoimmune diseaseInheritance: AR Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_017950.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CCDC40 | NM_017950.4 | MANE Select | c.648C>A | p.Asp216Glu | missense | Exon 4 of 20 | NP_060420.2 | ||
| CCDC40 | NM_001243342.2 | c.648C>A | p.Asp216Glu | missense | Exon 4 of 18 | NP_001230271.1 | |||
| CCDC40 | NM_001330508.2 | c.648C>A | p.Asp216Glu | missense | Exon 4 of 11 | NP_001317437.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CCDC40 | ENST00000397545.9 | TSL:5 MANE Select | c.648C>A | p.Asp216Glu | missense | Exon 4 of 20 | ENSP00000380679.4 | ||
| CCDC40 | ENST00000374876.4 | TSL:1 | c.648C>A | p.Asp216Glu | missense | Exon 4 of 9 | ENSP00000364010.4 | ||
| CCDC40 | ENST00000374877.7 | TSL:5 | c.648C>A | p.Asp216Glu | missense | Exon 4 of 18 | ENSP00000364011.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1461232Hom.: 0 Cov.: 33 AF XY: 0.00000413 AC XY: 3AN XY: 726894 show subpopulations
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Primary ciliary dyskinesia Uncertain:1
The p.D216E variant (also known as c.648C>A), located in coding exon 4 of the CCDC40 gene, results from a C to A substitution at nucleotide position 648. The aspartic acid at codon 216 is replaced by glutamic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at